ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,777.70
1.25%
S&P ASX All Technology
3,037.40
3.24%
Brent Oil
79.27
0.67%
US Dollar vs AUD
1.52054
0.23%
Bitcoin
60,731.83
-1.63%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) News

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RXRX
DateTimeSourceHeadlineSymbolCompany
09/08/202419:44IH Market NewsTSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/08/202407:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/08/202406:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/08/202404:41GlobeNewswire Inc.CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/08/202402:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202422:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202422:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202421:39GlobeNewswire Inc.Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End CapabilitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202421:30GlobeNewswire Inc.Recursion Provides Business Updates and Reports Second Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202415:32GlobeNewswire Inc.Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MTNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202403:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
07/08/202406:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
07/08/202406:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/08/202407:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/08/202406:01GlobeNewswire Inc.Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8thNASDAQ:RXRXRecursion Pharmaceuticals Inc
30/07/202408:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
26/07/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
26/07/202406:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/07/202406:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/07/202408:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/07/202408:52Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
12/07/202406:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/07/202406:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/07/202400:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
11/07/202406:41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
11/07/202402:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
10/07/202406:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
10/07/202406:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
27/06/202412:07GlobeNewswire Inc.Recursion Announces Pricing of $200 Million Public Offering of Class A Common StockNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX

Your Recent History

FTSE
UKX
FTSE 100
ASX
WES
Wesfarmers
NYSE
XOM
Exxon Mobil
ASX
WDC
Westfield
ASX
TLS
Telstra
FX
AUDCAD
AUD vs CAD
ASX
BHP
BHP
NYSE
MCD
McDonalds
ASX
XMM
S&P ASX 300 Metals and M...
NASDAQ
AAPL
Apple
ASX
AMP
AMP
NYSE
KO
Coca Cola
ASX
WOW
Woolworths
ASX
CSL
CSL
ASX
RIO
Rio Tinto
ASX
CBA
Commonwealth Bank Of Aus...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved